Oculis Holding AG.
OCS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Oculis Holding AG is a biopharmaceutical company focused on developing and commercializing innovative topical treatments for ophthalmic diseases. Their primary focus is on addressing unmet needs in eye care through non-invasive drug delivery methods. The company's pipeline includes product candidate...Show More
Better Health for All
20
Oculis Holding AG's core business is dedicated to developing treatments for ophthalmic and neuro-ophthalmic diseases with unmet medical needs, including acute optic neuritis, diabetic macular edema, and dry eye disease.
1
Its product candidates (OCS-01, OCS-05, OCS-02) are in clinical trials, with positive topline results reported for OCS-05 in a Phase 2 trial and OCS-02 in a Phase 2b trial.
2
For OCS-02, ocular treatment-emergent adverse events were 11.5% in the drug group and 10.2% in the vehicle group, all described as mild and transient with no serious ocular adverse events observed.
3
However, the rubric's safety thresholds are based on 'per million users,' which is not directly comparable to clinical trial percentages. Oculis invested CHF 52.1 million ($59.1 million) in R&D in FY2024 and CHF 14.8 million ($16.4 million) in Q1 2025.
4
The company secured a $100 million equity financing in February 2025, with net proceeds specifically allocated to advance its clinical development pipeline.
5
Oculis has an Expanded Access Program (EAP) policy to provide investigational therapies to patients outside of clinical trials for serious or life-threatening conditions with no suitable alternative treatment.
6
However, the policy states that the investigational therapy must not compromise broader development programs or interfere with clinical trials, indicating limited flexibility in its approach to access.
7
Fair Money & Economic Opportunity
0
No evidence available to assess Oculis Holding AG on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The provided articles do not contain specific, quantitative data points for any of the KPIs under the 'Fair Pay & Worker Respect' value. While one article mentions that employees in Iceland and France are represented by a labor union or covered under a collective bargaining agreement, no specific percentage of the total workforce is provided to score the 'collective_bargaining_share' KPI.
1
Information regarding living wage coverage, CEO to median pay ratio, safety incident rates, pay equity, worker engagement, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage is not available in the provided texts.
Fair Trade & Ethical Sourcing
0
No specific data points or metrics related to fair trade and ethical sourcing, including fair-trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, were found in the provided articles for Oculis Holding AG.
1
Honest & Fair Business
0
No evidence available to assess Oculis Holding AG on Honest & Fair Business.
Kind to Animals
0
Oculis Holding AG, a biopharmaceutical company, utilizes animal models and conducts animal toxicology studies as part of its drug development process.
1
For instance, animal models of neuroinflammation and neurodegeneration were used for Privosegtor,
2
and OPTIREACH® involved animal proof-of-concept studies.
3
The FDA placed OCS-05 on clinical hold in 2016, requiring more animal toxicology data,
4
which indicates a reliance on animal testing for regulatory approval. However, the provided articles do not contain specific, concrete data points regarding the company's animal testing policy, the volume of animals used, or any investment in animal-free alternatives.
5
Therefore, these KPIs cannot be scored based on the available evidence.
No War, No Weapons
0
No evidence available to assess Oculis Holding AG on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Oculis Holding AG on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles, which primarily focus on financial reporting, regulatory actions, and clinical trial progress, do not contain specific, concrete data points related to Oculis Holding AG's community engagement, cultural impact assessments, local employment, grievance mechanisms, or any other metrics relevant to the 'Respect for Cultures & Communities' value. The articles explicitly state significant data gaps regarding these specific metrics, including community engagement, reinvestment, cultural impact assessments, and compliance with FPIC processes.
1
Safe & Smart Tech
10
Oculis collects only necessary data for its services or recruitment, retaining it as long as the service is used or for a reasonable period after termination, unless legally required.
1
Users have comprehensive control over their data, including the ability to access, correct, request erasure, withdraw consent, object to processing, and obtain data portability in a machine-readable format.
2
The company states it complies with applicable data privacy laws, including those outside of Switzerland, and uses Standard Contractual Clauses or EU Model Clauses for data transfers outside the EEA.
3
No documented data breaches or incidents of unauthorized data use are reported in the provided articles.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Oculis Holding AG on Zero Waste & Sustainable Products.